12 Month Price Forecast For IVVD
Distance to IVVD Price Forecasts
IVVD Price Momentum
🤔 Considering Invivyd (IVVD)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 22, 2025 10:37 PM UTC
IVVD Analyst Ratings & Price Targets
Based on our analysis of 7 Wall Street analysts, IVVD has a consensus that is bullish. The median price target is $9.00, with forecasts ranging from $1.00 to $10.00. Currently, there are 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings.
With IVVD currently trading at $0.41, the median price forecast suggests a 2,108.6% upside. The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 2,354.0% upside, while Matthew Harrison at Morgan Stanley provides the most conservative target, suggesting a 145.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IVVD Analyst Consensus
IVVD Price Target Range
Latest IVVD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IVVD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $10.00 |
| Nov 20, 2024 | Morgan Stanley | Maxwell Skor | Overweight | Maintains | $3.55 |
| Nov 14, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $9.00 |
| Oct 30, 2024 | EF Hutton | Jason Kolbert | Buy | Initiates | $9.00 |
| Oct 29, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $15.00 |
| Sep 3, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $15.00 |
| Aug 30, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $15.00 |
| Aug 27, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $15.00 |
| May 24, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $15.00 |
| May 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $15.00 |
| Apr 5, 2024 | Guggenheim | Evan Wang | Buy | Upgrade | $9.00 |
| Mar 26, 2024 | Morgan Stanley | Maxwell Skor | Overweight | Upgrade | $10.00 |
| Mar 25, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $15.00 |
| Jan 18, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $15.00 |
| Dec 19, 2023 | Morgan Stanley | Jeffrey Hung | Equal-Weight | Upgrade | $4.00 |
| Aug 14, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jul 18, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jun 23, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| May 15, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| May 1, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Initiates | $5.00 |
Stocks Similar to Invivyd Inc
The following stocks are similar to Invivyd based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Invivyd Inc (IVVD) Financial Data
Invivyd Inc has a market capitalization of $91.88M with a P/E ratio of -0.2x. The company generates $2.26M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +310.8% quarter-over-quarter, while maintaining an operating margin of -2,175.2% and return on equity of -96.6%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Invivyd Inc (IVVD) Company Overview
About Invivyd Inc
Develops antibody-based treatments for infectious diseases.
Invivyd, Inc. operates as a commercial-stage biopharmaceutical company focusing on developing and commercializing antibody-based therapies. The company generates revenue through the sale of its investigational monoclonal antibodies and collaborations for research and discovery with other organizations.
Invivyd's pipeline includes several candidates targeting COVID-19, including PEMGRADA, VYD2311, and adintrvimab, along with candidates for seasonal influenza. The company collaborates with Adimab, LLC and the Scripps Research Institute to enhance its research capabilities. Founded in 2020 and based in Waltham, Massachusetts, Invivyd was previously known as Adagio Therapeutics, Inc.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
94
CEO
Ms. Heidi Spurling M.S.
Country
United States
IPO Year
2021
Website
invivyd.comInvivyd Inc (IVVD) Latest News & Analysis
Invivyd, Inc. (Nasdaq: IVVD) reported new data showing that its treatments PEMGARDA™ and VYD2311 maintain neutralizing activity against the dominant SARS-CoV-2 variant XEC, which, along with KP.3.1.1, comprised 69% of U.S. variants.
Positive neutralization data for Invivyd’s treatments against dominant SARS-CoV-2 variants signals strong market potential, boosting investor confidence in the company’s future growth and resilience.
Invivyd, Inc. (NASDAQ:IVVD) will hold its Q3 2024 earnings conference call on November 14, 2024, at 08:30 AM ET. Key company executives will participate in the call.
The upcoming earnings call for Invivyd, Inc. provides insights into financial performance and strategic direction, influencing stock valuation and investor sentiment.
Invivyd, Inc. announced the upload of preprints from its CANOPY Phase 3 trial of pemivibart, an investigational mAb for COVID-19 PrEP, showing long-term protection against JN.1 sublineages.
The announcement of promising Phase 3 trial results for Invivyd's monoclonal antibody could indicate potential market growth and revenue opportunities, impacting stock performance positively.
Invivyd, Inc. (Nasdaq: IVVD) reported its Q3 2024 financial results on Nov. 14, 2024, focusing on advancements in protection against viral infectious diseases.
Invivyd's quarterly financial results and business highlights can impact stock performance and investor sentiment, indicating growth potential and market confidence in its viral protection products.
Invivyd, Inc. (IVVD) reported a quarterly loss of $0.51 per share, exceeding the expected loss of $0.33, compared to a loss of $0.36 per share in the same quarter last year.
Invivyd's larger-than-expected quarterly loss signals potential operational challenges and may impact investor confidence, affecting stock performance and future funding prospects.
Invivyd, Inc. announced that The New England Journal of Medicine published a letter on its PEMGARDA™ EUA pathway and updated correlate of protection for COVID-19 prevention using monoclonal antibodies.
The NEJM's publication on Invivyd's PEMGARDA™ EUA pathway enhances credibility and could drive investor interest, impacting stock performance and market perception of the company's future prospects.
Frequently Asked Questions About IVVD Stock
What is Invivyd Inc's (IVVD) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Invivyd Inc (IVVD) has a median price target of $9.00. The highest price target is $10.00 and the lowest is $1.00.
Is IVVD stock a good investment in 2025?
According to current analyst ratings, IVVD has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.41. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for IVVD stock?
Wall Street analysts predict IVVD stock could reach $9.00 in the next 12 months. This represents a 2,108.6% increase from the current price of $0.41. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Invivyd Inc's business model?
Invivyd, Inc. operates as a commercial-stage biopharmaceutical company focusing on developing and commercializing antibody-based therapies. The company generates revenue through the sale of its investigational monoclonal antibodies and collaborations for research and discovery with other organizations.
What is the highest forecasted price for IVVD Invivyd Inc?
The highest price target for IVVD is $10.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 2,354.0% increase from the current price of $0.41.
What is the lowest forecasted price for IVVD Invivyd Inc?
The lowest price target for IVVD is $1.00 from Matthew Harrison at Morgan Stanley, which represents a 145.4% increase from the current price of $0.41.
What is the overall IVVD consensus from analysts for Invivyd Inc?
The overall analyst consensus for IVVD is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are IVVD stock price projections?
Stock price projections, including those for Invivyd Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
